Table 2.
Association between HHLA2, CD8 and Clinicopathologic Parameters
| Clinicopathologic parameters |
Total | HHLA2 | χ2 | CD8 | χ2 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Low (n=61) | High (n= 73) | (p value) | <60 (n = 67) | ≥60 (n= 67) | (p value) | ||||||||||
| Age classes | |||||||||||||||
| <60 y | 88 | 41 (46.6%) | 47 (53.4%) | χ2 =0.118 | 44 (50%) | 44 (50.0%) | χ2 =0.0 | ||||||||
| ≥60 y | 46 | 20 (43.5%) | 26 (56.5) | p=0.731 | 23 (50 %) | 23 (50 %) | P=1.0 | ||||||||
| Sex | |||||||||||||||
| Male | 75 | 33 (44.0%) | 42 (56.0%) | χ2 =0.159 | 44 (58.7%) | 31 (41.3%) | χ2 =5.12 | ||||||||
| Female | 59 | 28 (47.5%) | 31 (52.5%) | p=0.690 | 23 (39.0%) | 36 (61.0%) | P=0.024* | ||||||||
| Site | |||||||||||||||
| Right | 49 | 23 (46.9%) | 26 (53.1%) | χ2 =0.062 | 29 (59.2%) | 20 (40.8%) | χ2 =2.61 | ||||||||
| Left | 85 | 38 (44.7%) | 47 (55.3%) | p=0.803 | 38 (44.7%) | 47 (55.3%) | P=0.106 | ||||||||
| Size | |||||||||||||||
| ≤6 | 79 | 37 (46.8%) | 42 (53.2%) | χ2 =0.134 | 38 (48.1%) | 41 (51.9%) | χ2 =0.278 | ||||||||
| >6 | 55 | 24 (43.6%) | 31 (56.4%) | P=0.715 | 29 (52.7%) | 26 (47.3%) | P=0.598 | ||||||||
| Histological type | |||||||||||||||
| Adenocarcinoma NOS | 110 | 50 (45.5%) | 60 (54.5%) | MC=0.057 | 50 (45.5%) | 60 (54.5%) | MC | ||||||||
| Mucinous adenocarcinoma | 18 | 8 (44.4%) | 10 (55.6%) | P=0.972 | 11 (61.1%) | 7 (38.9%) | P=0.015* | ||||||||
| Signet ring carcinoma | 6 | 3 (50%) | 3 (50%) | 6 ( 100%) | 0 ( 0%) | ||||||||||
| Adenocarcinoma NOS grade (n= 110) | |||||||||||||||
| Low | 107 | 50 (46.7%) | 57 (53.3%) | FET=2.57 | 49 (45.79%) | 58 (54.2%) | FET | ||||||||
| High | 3 | 0 (0%) | 3 (100%) | P=0.249 | 1 (33.3%) | 2 (66.7%) | P=1.0 | ||||||||
| TILs | |||||||||||||||
| Low | 50 | 19 (38%) | 31 (62%) | χ2 =2.27 | 35 (70.0%) | 15 (30.0%) | χ2 =21.38 | ||||||||
| Moderate | 51 | 27 (52.9%) | 24 (47.1%) | P=0.321 | 26 (51.0%) | 25 (49.0%) | P≤0.001* | ||||||||
| High | 33 | 15 (45.5%) | 18 (54.5%) | 6 (18.2%) | 27 (81.8%) | ||||||||||
| Tumor budding | |||||||||||||||
| Low | 90 | 44 (48.9%) | 46 (51.1%) | χ2 =1.28 | 40 (44.4%) | 50 (55.6%) | χ2 =3.58 | ||||||||
| Moderate | 24 | 9 (37.5%) | 15 (62.5%) | P=0.527 | 14 (58.3%) | 10 (41.7%) | P=0.167 | ||||||||
| High | 20 | 8 (40%) | 12 (60%) | 13 (65.0%) | 7 (35.0%) | ||||||||||
| Tumor deposits | |||||||||||||||
| Present | 15 | 6 (40%) | 9 (60%) | χ2 =0.208 | 12 (80.0%) | 3 (20.0%) | χ2 =6.08 | ||||||||
| Absent | 119 | 55(46.2%) | 64 (53.8%) | P=0.649 | 55 (46.2%) | 64 (53.8%) | P=0.014* | ||||||||
| LVI | |||||||||||||||
| Present | 79 | 31(39.2%) | 48 (60.8%) | χ2 =3.06 | 45 (57.0%) | 34 (43.0%) | χ2 =3.73 | ||||||||
| Absent | 55 | 30 (54.5%) | 25 (45.5%) | P=0.08 | 22 (40.0%) | 33 (60.0%) | P=0.053 | ||||||||
| PNI | |||||||||||||||
| Present | 37 | 19 (51.4%) | 18 (48.6%) | χ2 =0.700 | 20 (54.1%) | 17 (45.9%) | χ2 =0.336 | ||||||||
| Absent | 97 | 42 (43.3%) | 55 (56.7%) | P=0.403 | 47 (48.5%) | 50 (51.5%) | P=0.562 | ||||||||
| Tumor depth of invasion | |||||||||||||||
| T2 | 17 | 13 (76.5%) | 4 (23.5%) | χ2MC =10.58 | 10 (58.8%) | 7 (41.2%) | χ2 =0.635 | ||||||||
| T3 | 102 | 45 (44.1%) | 57 (55.9%) | P=0.005* | 50 (49.0%) | 52 (51.0%) | P=0.728 | ||||||||
| T4 | 15 | 3 (20%) | 12 (80%) | 7 (46.7%) | 8 (53.3%) | ||||||||||
| Lymph node metastasis | |||||||||||||||
| N0 | 77 | 43 (55.8%) | 34 (44.2%) | χ2 =9.17 | 33 (42.9%) | 44 (57.1%) | χ2 =5.45 | ||||||||
| N1 | 31 | 12 (38.7%) | 19 (61.3%) | P=0.01* | 16 (51.6%) | 15 (48.4%) | P=0.066 | ||||||||
| N2 | 26 | 6 (23.1%) | 20 (76.9%) | 18 (69.2%) | 8 (30.8%) | ||||||||||
| Distant metastasis | |||||||||||||||
| M 0 | 126 | 60 (47.6%) | 66 (52.4%) | χ2 =3.74 | 60 (52.4%) | 66 (52.4%) | χ2 =4.78 | ||||||||
| M 1 | 8 | 1 (12.5%) | 7 (87.5%) | P=0.053 | 7 (87.5%) | 1 (12.5%) | P=0.029* | ||||||||
| AJCC stage | |||||||||||||||
| Stage I | 12 | 10 (83.3%) | 2 (16.7%) | χ2MC =14.69 | 5 (41.7%) | 7 (58.3%) | MC | ||||||||
| stage II | 63 | 33 (52.4%) | 30 (47.6%) | P=0.002* | 27 (42.9%) | 36 (57.1%) | P=0.086 | ||||||||
| Stage III | 51 | 17 (33.3%) | 34 (66.7%) | 28 (54.9%) | 23 (45.1%) | ||||||||||
| Stage IV | 8 | 1 (12.5%) | 7 (87.5%) | 7 (87.5%) | 1 (12.5%) | ||||||||||
| Local recurrence | |||||||||||||||
| Yes | 31 | 15 (48.4%) | 57 (55.3%) | χ2 =0.133 | 14 (45.2%) | 17 (54.8%) | χ2 =0.378 | ||||||||
| No | 103 | 46 (44.7%) | 16 (51.6%) | P=0.837 | 53 (51.5%) | 50 (48.5%) | P=0.539 | ||||||||
| Distant recurrence | |||||||||||||||
| Yes | 31 | 8 (25.8%) | 23 (74.2%) | χ2 =6.32 | 20 (64.5%) | 11 (35.5%) | χ2 =3.39 | ||||||||
| No | 103 | 53 (51.5%) | 50 (48.5%) | P=0.012* | 47 (45.6%) | 56 (54.4%) | P=0.065 | ||||||||
| Fate of patient | χ2 =0.588 | ||||||||||||||
| Died | 96 | 38 (39.6%) | 58 (60.4%) | χ2 =4.82 | 46 (47.9%) | 50 (52.1%) | P=0.443 | ||||||||
| Survived | 38 | 23 (60.5%) | 15 (39.5%) | P=0.028* | 21 (55.3%) | 17 (44.7%) | |||||||||
| CD8 | |||||||||||||||
| <60 | 67 | 33(49.3%) | 34 (50.7 %) | χ2 =0.752 | |||||||||||
| ≥60 | 67 | 28(41.8%) | 39 (58.2%) | P=0.386 | |||||||||||
χ2, Chi-Square test; FET, Fisher's Exact Test; MC, Monte carlo test P, Probability value; *, statistically significant (P<0.05).